These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28596255)

  • 1. Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera.
    Gangaraju R; Kim SJ; Dong JF; Swierczek S; Prchal JT
    J Natl Compr Canc Netw; 2017 Jun; 15(6):757-760. PubMed ID: 28596255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
    Kiladjian JJ; Cassinat B; Chevret S; Turlure P; Cambier N; Roussel M; Bellucci S; Grandchamp B; Chomienne C; Fenaux P
    Blood; 2008 Oct; 112(8):3065-72. PubMed ID: 18650451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
    Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
    J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C.
    Kitano K; Gibo Y; Kamijo A; Furuta K; Oguchi S; Joshita S; Takahashi Y; Ishida F; Matsumoto M; Uemura M; Fujimura Y
    Haematologica; 2006 Aug; 91(8 Suppl):ECR34. PubMed ID: 16923518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
    Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S
    Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
    Quintás-Cardama A; Abdel-Wahab O; Manshouri T; Kilpivaara O; Cortes J; Roupie AL; Zhang SJ; Harris D; Estrov Z; Kantarjian H; Levine RL; Verstovsek S
    Blood; 2013 Aug; 122(6):893-901. PubMed ID: 23782935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can pegylated interferon improve the outcome of polycythemia vera patients?
    Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
    J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.
    Shimoda K; Qin A; Komatsu N; Kirito K
    Int J Hematol; 2024 Aug; 120(2):151-156. PubMed ID: 38951434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
    Kiladjian JJ; Cassinat B; Turlure P; Cambier N; Roussel M; Bellucci S; Menot ML; Massonnet G; Dutel JL; Ghomari K; Rousselot P; Grange MJ; Chait Y; Vainchenker W; Parquet N; Abdelkader-Aljassem L; Bernard JF; Rain JD; Chevret S; Chomienne C; Fenaux P
    Blood; 2006 Sep; 108(6):2037-40. PubMed ID: 16709929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.
    Larsen TS; Bjerrum OW; Pallisgaard N; Andersen MT; Møller MB; Hasselbalch HC
    Ann Hematol; 2008 Oct; 87(10):847-50. PubMed ID: 18481066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
    O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
    Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
    Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I treat polycythemia vera.
    Passamonti F
    Blood; 2012 Jul; 120(2):275-84. PubMed ID: 22611155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature.
    Al-Husban N; Al-Kuran O
    J Med Case Rep; 2018 Jun; 12(1):147. PubMed ID: 29855343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-alpha 2a in a patient with polycythemia vera.
    Ishii T; Xu M; Zhao Y; Hu WY; Ciurea S; Bruno E; Hoffman R
    Leukemia; 2007 Feb; 21(2):373-4. PubMed ID: 17122864
    [No Abstract]   [Full Text] [Related]  

  • 20. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
    Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
    Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.